ResearcherHarvard UniversityActive in the last 2 years
Girgis Obaid
Matched on ORCID iD 0000-0002-9452-4467; OpenAlex author ID A5021133351; NIH RePORTER profile ID 12212817. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 10
2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 grant
Papers 7
- Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.jphotobiol.2023.112811↗
- Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer. Co-author DOI 10.1002/advs.202104594↗
- Orthotopic Models of Pancreatic Cancer to Study PDT. Co-author DOI 10.1007/978-1-0716-2099-1_12↗
- Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids. Co-author DOI 10.1021/acs.molpharmaceut.2c00260↗
- NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. First author DOI 10.3390/jcm9082390↗
- Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2019.119421↗
- Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towar… Co-author DOI 10.1021/acs.nanolett.9b00859↗
Grants 1
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tayyaba Hasan · 7 shared papers, 2019–2024 · strength 1.13
- Paper Orthotopic Models of Pancreatic Cancer to Study PDT. DOI 10.1007/978-1-0716-2099-1_12↗
- Paper Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer. DOI 10.1016/j.jphotobiol.2023.112811↗
- Paper Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Sph… DOI 10.1021/acs.molpharmaceut.2c00260↗
- Shazia Bano · 4 shared papers, 2019–2024 · strength 0.59
- Paper Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer. DOI 10.1016/j.jphotobiol.2023.112811↗
- Paper NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targe… DOI 10.3390/jcm9082390↗
- Paper Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancrea… DOI 10.1002/advs.202104594↗
- Mari A. Mino-Kenudson · 2 shared papers, 2022–2024 · strength 0.38
- Paper Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer. DOI 10.1016/j.jphotobiol.2023.112811↗
- Paper Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancrea… DOI 10.1002/advs.202104594↗
- Anne‐Laure Bulin · 2 shared papers, 2019 · strength 0.19
- Paper Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D c… DOI 10.1016/j.biomaterials.2019.119421↗
- Paper Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Ac… DOI 10.1021/acs.nanolett.9b00859↗
- Mans Broekgaarden · 2 shared papers, 2019 · strength 0.19
- Paper Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D c… DOI 10.1016/j.biomaterials.2019.119421↗
- Paper Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Ac… DOI 10.1021/acs.nanolett.9b00859↗
- Mohammad Ahsan Saad · 1 shared paper, 2022 · strength 0.17
- Brian W. Pogue · 1 shared paper, 2020 · strength 0.13
- Sriram R. Anbil · 1 shared paper, 2019 · strength 0.10
- Srivalleesha Mallidi · 1 shared paper, 2019 · strength 0.09
- Diane M. Simeone · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.